22nd Century Group, Inc.: 22nd Century Group Reports Second Quarter 2026 Financial Results
22nd Century Group (Nasdaq: XXII) reported Q2 2026 results for the quarter ended June 30, 2026. Net revenues fell to $2.9 million from $4.1 million, with operating loss of $3.3 million and net loss of $3.3 million. Cash was $6.1 million with no debt. The company expanded Pinnacle VLN retail distribution and launched Pinnacle Pure.
How this was made
The 30-second read
Why it matters
Q2 results show continued top-line softness and loss expansion, while management emphasizes retail footprint growth, new product introductions, and early promotional lift tied to unit sales and trials.
Market read
Traders can reassess near-term risk around cash burn and whether VLN commercialization is progressing fast enough to reverse revenue and margin trends.
What to watch
Operating expenses rose to $3.0M and adjusted EBITDA loss widened, so investors may focus on burn rate and whether the company can reach EBITDA breakeven before cash becomes the binding constraint.
Background
22nd Century Group is commercializing FDA-authorized reduced-nicotine (VLN) cigarettes using its proprietary technology, with Pinnacle-branded products expanding through retail channels.
Ticker impact
22nd Century reported Q2 2026 results, with net revenues down to $2.9M and cash of $6.1M, plus VLN retail expansion updates.
Near-term trading likely hinges on whether investors view the retail expansion and VLN reorder momentum as offsetting the ongoing cash burn.
The article provides fresh quarterly financial datapoints (revenues, losses, cash) and new operational milestones (store adds, new product launches, California entry), but it does not include guidance, regulatory outcomes, or a clear inflection in VLN revenue scale.
Market effects
Adds incremental evidence on execution and commercialization pace for reduced-nicotine combustible products, relevant to the tobacco harm-reduction niche.
Metro New York and northern New Jersey store expansion and California launch could influence regional convenience and specialty retail stocking dynamics.
Limited, as the updates are primarily US retail distribution and FDA engagement without international rollouts or cross-border regulatory actions.
Counterpoint
VLN revenue remains tiny ($0.03M) versus total revenues, so the store-count growth may not yet translate into material financial improvement.
Key entities
- company22nd Century Group, Inc.
Nasdaq-listed reduced-nicotine tobacco company reporting Q2 2026 financial results and VLN commercialization updates.
- product_categoryVLN (reduced-nicotine) cigarettes
Core commercialization focus, with management citing expanded retail distribution and reorder activity.
- regulatory_stakeholdersFDA regulators and public-health stakeholders
Company states it remains engaged, but the article does not disclose any new FDA decision.
